Remidio Launches AI-Powered Ultra-Widefield Retinal Imaging to Revolutionise Neonatal Eye Care

Published: 06 Nov 2025

Author: Precedence Research

Share :

Medtech innovator Remidio Innovative Solutions has launched its latest innovation, the Neubo 130. This artificial intelligence-powered ultra-widefield retinal imaging system is designed with neonatal care in mind. The device revolutionises the process of diagnosis and follow-up of Retinopathy of Prematurity (ROP) and other eye diseases in babies. Automated, dependable imaging technologies, such as Neubo 130, are essential tools for hospitals and NICUs because of the critical diagnostic gap caused by a lack of specialised ROP clinicians.

Neubo 130 is an industrial optical engineering device that embeds edge-AI technology to provide real-time analysis, even without an internet connection, making it very convenient to use at a bedside. Its 130° field of view, through-the-lens brightness, and light-shaping technology deliver the same brightness and peripheral imaging. Clinicians can easily detect even the slightest retinal changes, which would otherwise be overlooked during traditional screening. Its design is easy to use and patient-friendly, and it reduces the number of retakes needed thanks to automated montage.

Neubo 130 is another example of Remidio's expansion, reflecting a strong desire to address global neonatal eye care. Remidio currently operates in 55 countries, has already screened more than 16 million patients, and uses its knowledge to achieve global scale for low-cost AI-powered screening. Neubo 130 is poised to become the new standard for neonatal retinal imaging, with a focus on precision, portability, and system intelligence. Remidio is transforming the quality of care of premature infants by making AI-powered diagnostics available at the bedside.

Executives’ Statements:

Dr. Anand Sivaraman, CEO, Remidio:

“The launch of Neubo 130 marks a major step forward in neonatal eye care. This platform is our bet on certainty, reframing ROP from a resource problem to an engineering solution. By enabling dependable, on-the-spot decisions at the bedside, we move from ‘screening when possible’ to ‘protecting vision as standard.’ Our goal is to ensure that no premature baby goes without accurate, timely retinal assessment, regardless of location.”

Dr. Anand Vinekar, Professor & Head, ROP Services, Narayana Nethralaya:

“With affordable imaging and AI-driven triage systems like Remidio’s Neubo 130, we can bring early and accurate ROP detection to even the most remote centers. The future of screening is simple, intelligent, and accessible, empowering every healthcare worker to protect a baby’s vision from the very first exam.”